NYSEAMERICAN : KAPA
Kairos Pharma, Ltd. — Financial statements
Healthcare · Biotechnology · United States
Last price 0.53 USD (Oct 30, 2026, 4:00 PM) · Market cap 1.79M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Selling, General & Admin | 3.51M | 3.44M | 1.93M | 1.63M | 484.00K | 1.76M |
| Research & Development | 2.45M | 2.13M | 414.00K | 82.00K | 87.00K | 183.00K |
| Operating Expenses | 5.96M | 5.57M | 2.34M | 1.71M | 571.00K | 1.94M |
| Operating Income | -5.96M | -5.57M | -2.34M | -1.71M | -571.00K | -1.94M |
| Interest Expense | -189.00K | -98.00K | -459.00K | -164.00K | ||
| Interest & Investment Income | 152.00K | 125.00K | ||||
| Other Non Operating Income (Expenses) | -670.00K | -20.00K | -38.00K | |||
| EBT Excluding Unusual Items | -5.80M | -5.45M | -3.20M | -1.81M | -1.05M | -2.15M |
| Other Unusual Items | 599.00K | |||||
| Pretax Income | -5.80M | -5.45M | -2.60M | -1.81M | -1.05M | -2.15M |
| Net Income | -5.80M | -5.45M | -2.60M | -1.81M | -1.05M | -2.15M |
| Net Income to Common | -5.80M | -5.45M | -2.60M | -1.81M | -1.05M | -2.15M |
| Shares Outstanding (Basic) | 2.98M | 2.63M | 1.62M | 1.48M | 1.46M | 1.31M |
| Shares Outstanding (Diluted) | 2.98M | 2.63M | 1.62M | 1.48M | 1.46M | 1.31M |
| EPS (Basic) | -1.95 | -2.07 | -1.60 | -1.22 | -0.72 | -1.64 |
| EPS (Diluted) | -1.95 | -2.07 | -1.60 | -1.22 | -0.72 | -1.64 |
| EBITDA | -5.82M | -5.41M | -2.18M | -1.55M | -411.00K | -1.84M |
| D&A For EBITDA | 142.00K | 160.00K | 160.00K | 160.00K | 160.00K | 98.00K |
| EBIT | -5.96M | -5.57M | -2.34M | -1.71M | -571.00K | -1.94M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | 2.63M | 4.49M | 1.27M | 93.00K | 437.00K | 73.00K |
| Cash & Short-Term Investments | 2.63M | 4.49M | 1.27M | 93.00K | 437.00K | 73.00K |
| Prepaid Expenses | 136.00K | 51.00K | 38.00K | 8.00K | ||
| Other Current Assets | 412.00K | 845.00K | 2.86M | |||
| Total Current Assets | 3.17M | 5.39M | 4.17M | 101.00K | 437.00K | 73.00K |
| Other Intangible Assets | 62.00K | 222.00K | 382.00K | 542.00K | 702.00K | |
| Long-Term Deferred Charges | 1.28M | 1.09M | 1.38M | 482.00K | 57.00K | |
| Total Assets | 4.46M | 6.54M | 5.77M | 965.00K | 1.04M | 775.00K |
| Accounts Payable | 265.00K | 199.00K | 992.00K | 2.40M | 1.63M | 1.55M |
| Short-Term Debt | 4.00K | 4.00K | 394.00K | |||
| Total Current Liabilities | 265.00K | 199.00K | 992.00K | 2.40M | 1.63M | 1.94M |
| Long-Term Debt | 638.00K | 582.00K | ||||
| Total Liabilities | 265.00K | 199.00K | 992.00K | 3.04M | 2.21M | 1.94M |
| Common Stock | 21.00K | 21.00K | 14.00K | 11.00K | 10.00K | 102.00K |
| Additional Paid-In Capital | 21.47M | 20.58M | 13.58M | 4.12M | 3.21M | 2.08M |
| Retained Earnings | -17.30M | -14.26M | -8.81M | -6.21M | -4.40M | -3.35M |
| Shareholders' Equity | 4.19M | 6.34M | 4.78M | -2.08M | -1.18M | -1.17M |
| Total Liabilities & Equity | 4.46M | 6.54M | 5.77M | 965.00K | 1.04M | 775.00K |
| Total Debt | 642.00K | 586.00K | 394.00K | |||
| Net Cash (Debt) | 2.63M | 4.49M | 1.27M | -549.00K | -149.00K | -321.00K |
| Net Cash Per Share | 0.88 | 1.71 | 0.78 | -0.37 | -0.10 | -0.25 |
| Filing Date Shares Outstanding | 3.39M | 3.06M | 2.38M | 1.51M | 1.48M | 1.73M |
| Total Common Shares Outstanding | 3.06M | 2.97M | 1.96M | 1.51M | 1.48M | 1.73M |
| Working Capital | 2.91M | 5.19M | 3.18M | -2.30M | -1.20M | -1.87M |
| Book Value Per Share | 1.37 | 2.13 | 2.43 | -1.38 | -0.80 | -0.68 |
| Tangible Book Value | 4.19M | 6.28M | 4.55M | -2.46M | -1.72M | -1.87M |
| Tangible Book Value Per Share | 1.37 | 2.11 | 2.32 | -1.63 | -1.17 | -1.08 |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Net Income | -5.80M | -5.45M | -2.60M | -1.81M | -1.05M | -2.15M |
| Depreciation & Amortization | 142.00K | 160.00K | 160.00K | 160.00K | 160.00K | 98.00K |
| Other Amortization | 154.00K | 56.00K | 408.00K | 144.00K | ||
| Stock-Based Compensation | 847.00K | 482.00K | 218.00K | 300.00K | ||
| Other Operating Activities | 1.30M | 2.17M | 100.00K | 913.00K | ||
| Change in Accounts Payable | -411.00K | -793.00K | 404.00K | 772.00K | 129.00K | 1.19M |
| Change in Other Net Operating Assets | -48.00K | -13.00K | -2.39M | -8.00K | ||
| Operating Cash Flow | -3.97M | -3.44M | -3.96M | 81.00K | -353.00K | -412.00K |
| Cash Acquisitions | -109.00K | |||||
| Investing Cash Flow | -109.00K | |||||
| Short-Term Debt Issued | 142.00K | |||||
| Long-Term Debt Issued | 3.60M | 925.00K | 350.00K | |||
| Total Debt Issued | 3.38M | 3.60M | 142.00K | 925.00K | 350.00K | |
| Short-Term Debt Repaid | -142.00K | -40.00K | -20.00K | |||
| Total Debt Repaid | -142.00K | -40.00K | -20.00K | |||
| Net Debt Issued (Repaid) | 3.38M | 3.60M | 885.00K | 330.00K | ||
| Issuance of Common Stock | 5.52M | 250.00K | ||||
| Other Financing Activities | 183.00K | 3.06M | -390.00K | -425.00K | -168.00K | |
| Financing Cash Flow | 3.56M | 6.66M | 5.13M | -425.00K | 717.00K | 580.00K |
| Net Cash Flow | -408.00K | 3.22M | 1.18M | -344.00K | 364.00K | 59.00K |
| Levered Free Cash Flow | -1.89M | -1.63M | -5.35M | 760.50K | 5.25K | 465.98K |
| Unlevered Free Cash Flow | -1.89M | -1.63M | -5.38M | 765.75K | -115.88K | 424.48K |
| Cash Interest Paid | 3.00K | |||||
| Change in Working Capital | -459.00K | -806.00K | -1.98M | 764.00K | 129.00K | 1.19M |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Market Capitalization | 1.81M | 14.78M | 19.53M | |||
| Enterprise Value | -811.19K | 9.21M | 16.45M | |||
| Last Close Price | 0.53 | 4.97 | 10.64 | |||
| PB Ratio | 0.39 | 2.33 | 4.09 | |||
| P/TBV Ratio | 0.43 | 2.35 | 4.29 | |||
| Debt / Equity Ratio | -0.31 | -0.50 | -0.34 | |||
| Net Debt / Equity Ratio | -0.63 | -0.71 | -0.27 | -0.26 | -0.13 | -0.28 |
| Net Debt / EBITDA Ratio | 0.45 | 0.83 | 0.58 | -0.35 | -0.36 | -0.17 |
| Quick Ratio | 9.91 | 22.57 | 1.28 | 0.04 | 0.27 | 0.04 |
| Current Ratio | 11.98 | 27.07 | 4.20 | 0.04 | 0.27 | 0.04 |
| Return on Equity (ROE) | -113.96% | -97.99% | -192.96% | |||
| Return on Assets (ROA) | -66.91% | -56.59% | -43.50% | -107.07% | -39.41% | -307.71% |
| Return on Capital Employed (ROCE) | -142.10% | -87.90% | -49.10% | 119.00% | 95.60% | 166.50% |
| Earnings Yield | -363.07% | -36.85% | -13.33% | |||
| Buyback Yield / Dilution | -46.73% | -62.27% | -9.38% | -1.42% | -11.86% | 3.12% |